• Publications
  • Influence
ESC Guidelines on the diagnosis and management of acute pulmonary embolism
Authors/Task Force Members: Stavros Konstantinides* (Chairperson) (Germany/ Greece), Adam Torbicki* (Co-chairperson) (Poland), Giancarlo Agnelli (Italy), Nicolas Danchin (France), David FitzmauriceExpand
[2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension].
The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) is constituted. Expand
Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 *
The Zar Review Group: I.J. Bousquet, N. Khaltaev, A. R. Rabe, J. Rosado-Pinto, G. Scadding, F. Simons, E. Togias, T. Valovirta, P. Vandenplas, D. Wang, M. Stoloff, O. Williams. Expand
Cellular and molecular pathobiology of pulmonary arterial hypertension.
Pulmonary arterial hypertension has a multifactorial pathobiology and recent genetic and pathophysiologic studies have emphasized the relevance of several mediators in this condition, including prostacyclin, nitric oxide, ET-1, angiopoietin- 1, serotonin, cytokines, chemokines, and members of the transforming-growth-factor-beta superfamily. Expand
Pulmonary arterial hypertension
The current state of art regarding to epidemiologic aspects of PH, diagnostic approaches and the current classification of PH are discussed as well as future treatments. Expand
Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension
Long-term CCB responders represent <10% of IPAH patients evaluated in a pulmonary vascular referral center, and during acute vasodilator testing, these patients showed significantly lower levels of both mean PAP and PVR, which reached near-normal values. Expand
Guidelines for the diagnosis and treatment of pulmonary hypertension
Guidelines and Expert Consensus Documents summarise and evaluate all currently available evidence on a particular issue with the aim to assist physicians in selecting the best management strategiesExpand
Pulmonary arterial hypertension in France: results from a national registry.
It is shown that PAH is detected late in the course of the disease, with a majority of patients displaying severe functional and hemodynamic compromise, and this contemporary registry highlights current practice. Expand
Riociguat for the treatment of pulmonary arterial hypertension.
Riociguat significantly improved exercise capacity and secondary efficacy end points in patients with pulmonary arterial hypertension and showed significant improvements in pulmonary vascular resistance, NT-proBNP levels, World Health Organization functional class, and time to clinical worsening. Expand